Singapore markets close in 3 hours 15 minutes
  • Straits Times Index

    3,178.31
    -21.95 (-0.69%)
     
  • Nikkei

    29,512.39
    +154.57 (+0.53%)
     
  • Hang Seng

    28,475.98
    -134.67 (-0.47%)
     
  • FTSE 100

    7,129.71
    +53.54 (+0.76%)
     
  • BTC-USD

    58,839.36
    +547.62 (+0.94%)
     
  • CMC Crypto 200

    1,559.36
    +123.58 (+8.61%)
     
  • S&P 500

    4,232.60
    +30.98 (+0.74%)
     
  • Dow

    34,777.76
    +229.26 (+0.66%)
     
  • Nasdaq

    13,752.24
    +119.44 (+0.88%)
     
  • Gold

    1,837.90
    +6.60 (+0.36%)
     
  • Crude Oil

    65.25
    +0.35 (+0.54%)
     
  • 10-Yr Bond

    1.5770
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,586.96
    -0.49 (-0.03%)
     
  • Jakarta Composite Index

    5,976.01
    +47.70 (+0.80%)
     
  • PSE Index

    6,317.41
    +58.70 (+0.94%)
     

Britain expects verdict on Pfizer's COVID-19 vaccine before AstraZeneca's - Times

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
FILE PHOTO: A woman walks past a sign outside Pfizer Headquarters in the Manhattan borough of New York City
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

(Reuters) - Senior sources in the British government expect that a verdict on whether Pfizer Inc-backed <PFE.N> COVID-19 vaccine works will be available before the results are in on AstraZeneca Plc's <AZN.L> competing vaccine, the Times reported.

Britain believes that the vaccine, which Pfizer is co-developing with Germany's BioNTech SE <22UAy.F>, could be ready to distribute before Christmas, the report said.

Pfizer's Chief Executive Albert Bourla has previously said the company could release data on whether or not the vaccine works as early as this month.

The U.S. drugmaker said this week if trials are successful the company expects to file for emergency authorization of the vaccine candidate from U.S. regulators shortly after it has enough safety data in late November.

Britain has agreed supply deals for six vaccine candidates including frontrunners from Pfizer and AstraZeneca.

(Reporting by Shubham Kalia in Bengaluru; Editing by Tom Hogue)